The Tumor–Lymphatic–Lymph Node Axis in Immune Checkpoint Inhibitor Response and Resistance
Lymphatics · 18.11.2026 · 4 (4) · 58
DOI: 10.3390/lymphatics4040058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lymphatics, online erschienen am 18.11.2026. Verfasst von Sree Manasa Puttamreddy und 2 weiteren Autor:innen. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors can produce durable tumor control, but their activity depends on immune processes extending beyond the tumor microenvironment. Lymphatic vessels and tumor-draining lymph nodes connect antigen release with dendritic-cell migration, T-cell priming, and the maintenance of progenitor populations capable of replenishing antitumor responses. The same network can promote deletional tolerance, regulatory-cell activity, and metastatic dissemination. This narrative review examines how these opposing functions influence checkpoint inhibitor response and resistance, with emphasis on the distinction between mechanistic evidence and clinical inference. Mouse studies establish roles for nodal dendritic cells, lymphatic endothelial PD-L1, and stem-like CD8+ T-cell reservoirs, while human tissue studies support related cellular and clonal relationships. VEGF-C illustrates the context dependence of this biology: lymphangiogenesis can enhance immune recruitment and checkpoint activity in some models while facilitating tolerance and metastasis in others. Surgery and nodal irradiation can interrupt immune communication, although compensatory drainage and treatment timing modify their effects. Randomized melanoma trials support neoadjuvant-inclusive checkpoint therapy, but do not establish lymph-node preservation as the mechanism of benefit. Candidate biomarkers integrating drainage, nodal architecture, dendritic-cell activity, and T-cell state remain investigational. Therapeutic development should therefore seek to preserve productive antigen presentation and immune-cell trafficking while controlling dissemination and suppressive signaling. Prospective studies with paired tumor, lymph-node, and blood sampling are needed before lymphatic measurements can guide patient selection or changes to established locoregional treatment.
Zitieren
APA
Puttamreddy, S. M., Khalid, Y., & Kareem, S. A. (2026). The Tumor–Lymphatic–Lymph Node Axis in Immune Checkpoint Inhibitor Response and Resistance. Lymphatics, 4(4), 58. https://doi.org/10.3390/lymphatics4040058
Vancouver
Puttamreddy SM, Khalid Y, Kareem SA. The Tumor–Lymphatic–Lymph Node Axis in Immune Checkpoint Inhibitor Response and Resistance. Lymphatics. 2026;4(4):58. doi:10.3390/lymphatics4040058
BibTeX
@article{Puttamreddy2026,
author = {Puttamreddy, Sree Manasa and Khalid, Yumna and Kareem, Saad Abdul},
title = {The Tumor–Lymphatic–Lymph Node Axis in Immune Checkpoint Inhibitor Response and Resistance},
journal = {Lymphatics},
year = {2026},
volume = {4},
number = {4},
pages = {58},
doi = {10.3390/lymphatics4040058}
}
EUVIMED